Review




Structured Review

Cubist Pharmaceuticals cyclic lipopeptides daptomycin
Cyclic Lipopeptides Daptomycin, supplied by Cubist Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cyclic+lipopeptides+daptomycin/cyclic+lipopeptides+daptomycin/pmc10685826-85-14-18
Average 90 stars, based on 1 article reviews
cyclic lipopeptides daptomycin - by Bioz Stars, 2026-10
90/100 stars

Images

Related Articles

other:

Article Title: Biotransformation-coupled mutasynthesis for the generation of novel pristinamycin derivatives by engineering the phenylglycine residue
Article Snippet: The most recent new compound classes that have been introduced to the market are cyclic lipopeptides (daptomycin by Cubist Pharmaceuticals in 2003) and oxazolidinones (linezolid by Pfizer in 2000).



Similar Products

90
Sangon Biotech daptomycin (cyclic lipopeptides)
Antibacterial efficacy by SCF in the absence or presence of valine. ( A ) Percent survival of MRSA2 in the presence of the indicated antibiotics with or without 5 mM valine. SCF, cefoperazone sodium and <t>sulbactam</t> sodium; ASPC, amoxicillin sodium clavulanate potassium. Antibiotic doses are as follows: 200 µg/mL for SCF; 300 µg/mL for ceftriaxone, cefradine, ceftazidime, cefazolin; 150 µg/mL for vancomycin; and 400 µg/mL for the others. ( B ) Percent survival of MRSA2 in the absence or presence of the indicated concentrations of SCF plus 5 mM valine. ( C ) Percent survival of MRSA2 in the absence or presence of the indicated concentrations of valine plus 200 µg/mL SCF. ( D ) Percent survival of MRSA2 in the absence or presence of the indicated incubation time with 5 mM valine and 200 µg/mL SCF. ( E ) Percent survival of 18 MRSA isolates (2.5 × 10 7 CFU/mL) in the absence or presence of 5 mM valine, 200 µg/mL SCF, and both. ( F ) Bacterial load of liver, kidney, and spleen of mice infected with MRSA2. Mice were intraperitoneally infected with 2.5 × 10 6 CFU of MRSA2 and divided into four groups, four male Balb/c mice per group. The four groups were separately intravenously injected with saline solution, 200 mg/kg SCF, 200 mg/kg valine, or both in an hour later. Spleen, kidney, and liver of these treated mice were collected at 24 h and homogenized for spot plate counting. ( G ) Percent survival of mice in the absence or presence of the indicated dose of SCF or/and the indicated dose of valine. Mice were intraperitoneally infected with 2.5 × 10 7 CFU of MRSA2 and divided into eight (sub)groups to be treated as the indicated post 1 h of infection, 10 mice per group. Survival of mice was monitored for 7 days. ( H ) Bacterial load of mouse thigh infected with MRSA2. Mice were intramuscularly infected with 2.8 × 10 5 CFU of MRSA2 and divided into four groups. The four groups were separately treated with saline solution, 200 mg/kg SCF, 200 mg/kg valine, or both post 2 h infection. The thigh muscle infected was collected at 26 h and homogenized for spot plate counting. ( I ) Percent survival of MRSA2 in the absence or presence of 5 mM leucine or isoleucine plus 200 µg/mL SCF. Data are mean ± SD from three biological replicates. *, P < 0.05; **, P < 0.01.
Daptomycin (Cyclic Lipopeptides), supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cyclic+lipopeptides+daptomycin/daptomycin++cyclic+lipopeptides+/pmc11748551-201-9-20
Average 90 stars, based on 1 article reviews
daptomycin (cyclic lipopeptides) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Cubist Pharmaceuticals cyclic lipopeptides daptomycin
Antibacterial efficacy by SCF in the absence or presence of valine. ( A ) Percent survival of MRSA2 in the presence of the indicated antibiotics with or without 5 mM valine. SCF, cefoperazone sodium and <t>sulbactam</t> sodium; ASPC, amoxicillin sodium clavulanate potassium. Antibiotic doses are as follows: 200 µg/mL for SCF; 300 µg/mL for ceftriaxone, cefradine, ceftazidime, cefazolin; 150 µg/mL for vancomycin; and 400 µg/mL for the others. ( B ) Percent survival of MRSA2 in the absence or presence of the indicated concentrations of SCF plus 5 mM valine. ( C ) Percent survival of MRSA2 in the absence or presence of the indicated concentrations of valine plus 200 µg/mL SCF. ( D ) Percent survival of MRSA2 in the absence or presence of the indicated incubation time with 5 mM valine and 200 µg/mL SCF. ( E ) Percent survival of 18 MRSA isolates (2.5 × 10 7 CFU/mL) in the absence or presence of 5 mM valine, 200 µg/mL SCF, and both. ( F ) Bacterial load of liver, kidney, and spleen of mice infected with MRSA2. Mice were intraperitoneally infected with 2.5 × 10 6 CFU of MRSA2 and divided into four groups, four male Balb/c mice per group. The four groups were separately intravenously injected with saline solution, 200 mg/kg SCF, 200 mg/kg valine, or both in an hour later. Spleen, kidney, and liver of these treated mice were collected at 24 h and homogenized for spot plate counting. ( G ) Percent survival of mice in the absence or presence of the indicated dose of SCF or/and the indicated dose of valine. Mice were intraperitoneally infected with 2.5 × 10 7 CFU of MRSA2 and divided into eight (sub)groups to be treated as the indicated post 1 h of infection, 10 mice per group. Survival of mice was monitored for 7 days. ( H ) Bacterial load of mouse thigh infected with MRSA2. Mice were intramuscularly infected with 2.8 × 10 5 CFU of MRSA2 and divided into four groups. The four groups were separately treated with saline solution, 200 mg/kg SCF, 200 mg/kg valine, or both post 2 h infection. The thigh muscle infected was collected at 26 h and homogenized for spot plate counting. ( I ) Percent survival of MRSA2 in the absence or presence of 5 mM leucine or isoleucine plus 200 µg/mL SCF. Data are mean ± SD from three biological replicates. *, P < 0.05; **, P < 0.01.
Cyclic Lipopeptides Daptomycin, supplied by Cubist Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cyclic+lipopeptides+daptomycin/cyclic+lipopeptides+daptomycin/pmc10685826-85-14-18
Average 90 stars, based on 1 article reviews
cyclic lipopeptides daptomycin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Eli Lilly cyclic lipopeptide daptomycin
Antibacterial efficacy by SCF in the absence or presence of valine. ( A ) Percent survival of MRSA2 in the presence of the indicated antibiotics with or without 5 mM valine. SCF, cefoperazone sodium and <t>sulbactam</t> sodium; ASPC, amoxicillin sodium clavulanate potassium. Antibiotic doses are as follows: 200 µg/mL for SCF; 300 µg/mL for ceftriaxone, cefradine, ceftazidime, cefazolin; 150 µg/mL for vancomycin; and 400 µg/mL for the others. ( B ) Percent survival of MRSA2 in the absence or presence of the indicated concentrations of SCF plus 5 mM valine. ( C ) Percent survival of MRSA2 in the absence or presence of the indicated concentrations of valine plus 200 µg/mL SCF. ( D ) Percent survival of MRSA2 in the absence or presence of the indicated incubation time with 5 mM valine and 200 µg/mL SCF. ( E ) Percent survival of 18 MRSA isolates (2.5 × 10 7 CFU/mL) in the absence or presence of 5 mM valine, 200 µg/mL SCF, and both. ( F ) Bacterial load of liver, kidney, and spleen of mice infected with MRSA2. Mice were intraperitoneally infected with 2.5 × 10 6 CFU of MRSA2 and divided into four groups, four male Balb/c mice per group. The four groups were separately intravenously injected with saline solution, 200 mg/kg SCF, 200 mg/kg valine, or both in an hour later. Spleen, kidney, and liver of these treated mice were collected at 24 h and homogenized for spot plate counting. ( G ) Percent survival of mice in the absence or presence of the indicated dose of SCF or/and the indicated dose of valine. Mice were intraperitoneally infected with 2.5 × 10 7 CFU of MRSA2 and divided into eight (sub)groups to be treated as the indicated post 1 h of infection, 10 mice per group. Survival of mice was monitored for 7 days. ( H ) Bacterial load of mouse thigh infected with MRSA2. Mice were intramuscularly infected with 2.8 × 10 5 CFU of MRSA2 and divided into four groups. The four groups were separately treated with saline solution, 200 mg/kg SCF, 200 mg/kg valine, or both post 2 h infection. The thigh muscle infected was collected at 26 h and homogenized for spot plate counting. ( I ) Percent survival of MRSA2 in the absence or presence of 5 mM leucine or isoleucine plus 200 µg/mL SCF. Data are mean ± SD from three biological replicates. *, P < 0.05; **, P < 0.01.
Cyclic Lipopeptide Daptomycin, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cyclic+lipopeptides+daptomycin/daptomycin/pm32209367-19-19-33
Average 90 stars, based on 1 article reviews
cyclic lipopeptide daptomycin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Millipore daptomycin cyclic lipopeptide antibiotic
Antibacterial efficacy by SCF in the absence or presence of valine. ( A ) Percent survival of MRSA2 in the presence of the indicated antibiotics with or without 5 mM valine. SCF, cefoperazone sodium and <t>sulbactam</t> sodium; ASPC, amoxicillin sodium clavulanate potassium. Antibiotic doses are as follows: 200 µg/mL for SCF; 300 µg/mL for ceftriaxone, cefradine, ceftazidime, cefazolin; 150 µg/mL for vancomycin; and 400 µg/mL for the others. ( B ) Percent survival of MRSA2 in the absence or presence of the indicated concentrations of SCF plus 5 mM valine. ( C ) Percent survival of MRSA2 in the absence or presence of the indicated concentrations of valine plus 200 µg/mL SCF. ( D ) Percent survival of MRSA2 in the absence or presence of the indicated incubation time with 5 mM valine and 200 µg/mL SCF. ( E ) Percent survival of 18 MRSA isolates (2.5 × 10 7 CFU/mL) in the absence or presence of 5 mM valine, 200 µg/mL SCF, and both. ( F ) Bacterial load of liver, kidney, and spleen of mice infected with MRSA2. Mice were intraperitoneally infected with 2.5 × 10 6 CFU of MRSA2 and divided into four groups, four male Balb/c mice per group. The four groups were separately intravenously injected with saline solution, 200 mg/kg SCF, 200 mg/kg valine, or both in an hour later. Spleen, kidney, and liver of these treated mice were collected at 24 h and homogenized for spot plate counting. ( G ) Percent survival of mice in the absence or presence of the indicated dose of SCF or/and the indicated dose of valine. Mice were intraperitoneally infected with 2.5 × 10 7 CFU of MRSA2 and divided into eight (sub)groups to be treated as the indicated post 1 h of infection, 10 mice per group. Survival of mice was monitored for 7 days. ( H ) Bacterial load of mouse thigh infected with MRSA2. Mice were intramuscularly infected with 2.8 × 10 5 CFU of MRSA2 and divided into four groups. The four groups were separately treated with saline solution, 200 mg/kg SCF, 200 mg/kg valine, or both post 2 h infection. The thigh muscle infected was collected at 26 h and homogenized for spot plate counting. ( I ) Percent survival of MRSA2 in the absence or presence of 5 mM leucine or isoleucine plus 200 µg/mL SCF. Data are mean ± SD from three biological replicates. *, P < 0.05; **, P < 0.01.
Daptomycin Cyclic Lipopeptide Antibiotic, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cyclic+lipopeptides+daptomycin/daptomycin+cyclic+lipopeptide+antibiotic/10__1128_slash_mbio__03027___20-177-9-13
Average 90 stars, based on 1 article reviews
daptomycin cyclic lipopeptide antibiotic - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Eli Lilly daptomycin is a cyclic lipopeptide
Antibacterial efficacy by SCF in the absence or presence of valine. ( A ) Percent survival of MRSA2 in the presence of the indicated antibiotics with or without 5 mM valine. SCF, cefoperazone sodium and <t>sulbactam</t> sodium; ASPC, amoxicillin sodium clavulanate potassium. Antibiotic doses are as follows: 200 µg/mL for SCF; 300 µg/mL for ceftriaxone, cefradine, ceftazidime, cefazolin; 150 µg/mL for vancomycin; and 400 µg/mL for the others. ( B ) Percent survival of MRSA2 in the absence or presence of the indicated concentrations of SCF plus 5 mM valine. ( C ) Percent survival of MRSA2 in the absence or presence of the indicated concentrations of valine plus 200 µg/mL SCF. ( D ) Percent survival of MRSA2 in the absence or presence of the indicated incubation time with 5 mM valine and 200 µg/mL SCF. ( E ) Percent survival of 18 MRSA isolates (2.5 × 10 7 CFU/mL) in the absence or presence of 5 mM valine, 200 µg/mL SCF, and both. ( F ) Bacterial load of liver, kidney, and spleen of mice infected with MRSA2. Mice were intraperitoneally infected with 2.5 × 10 6 CFU of MRSA2 and divided into four groups, four male Balb/c mice per group. The four groups were separately intravenously injected with saline solution, 200 mg/kg SCF, 200 mg/kg valine, or both in an hour later. Spleen, kidney, and liver of these treated mice were collected at 24 h and homogenized for spot plate counting. ( G ) Percent survival of mice in the absence or presence of the indicated dose of SCF or/and the indicated dose of valine. Mice were intraperitoneally infected with 2.5 × 10 7 CFU of MRSA2 and divided into eight (sub)groups to be treated as the indicated post 1 h of infection, 10 mice per group. Survival of mice was monitored for 7 days. ( H ) Bacterial load of mouse thigh infected with MRSA2. Mice were intramuscularly infected with 2.8 × 10 5 CFU of MRSA2 and divided into four groups. The four groups were separately treated with saline solution, 200 mg/kg SCF, 200 mg/kg valine, or both post 2 h infection. The thigh muscle infected was collected at 26 h and homogenized for spot plate counting. ( I ) Percent survival of MRSA2 in the absence or presence of 5 mM leucine or isoleucine plus 200 µg/mL SCF. Data are mean ± SD from three biological replicates. *, P < 0.05; **, P < 0.01.
Daptomycin Is A Cyclic Lipopeptide, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cyclic+lipopeptides+daptomycin/daptomycin/10__1039_slash_c9np00071b-56-35-61
Average 90 stars, based on 1 article reviews
daptomycin is a cyclic lipopeptide - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Millipore daptomycin cyclic lipopeptide
Selected antibiotics tested against B. burgdorferi
Daptomycin Cyclic Lipopeptide, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cyclic+lipopeptides+daptomycin/daptomycin+cyclic+lipopeptide/pmc04505243-86-0-3
Average 90 stars, based on 1 article reviews
daptomycin cyclic lipopeptide - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Cubist Pharmaceuticals molecular biology tools for the combinatorial biosynthesis of cyclic lipopeptides related to daptomycin
Selected antibiotics tested against B. burgdorferi
Molecular Biology Tools For The Combinatorial Biosynthesis Of Cyclic Lipopeptides Related To Daptomycin, supplied by Cubist Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cyclic+lipopeptides+daptomycin/molecular+biology+tools+for+the+combinatorial+biosynthesis+of+cyclic+lipopeptides+related+to+daptomycin/pm24862629-59-21-4
Average 90 stars, based on 1 article reviews
molecular biology tools for the combinatorial biosynthesis of cyclic lipopeptides related to daptomycin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Cubist Pharmaceuticals cyclic lipopeptide antibiotics daptomycin cubicin
Infection Parameter
Cyclic Lipopeptide Antibiotics Daptomycin Cubicin, supplied by Cubist Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cyclic+lipopeptides+daptomycin/daptomycin+cubicin/pmc03184046-173-7-12
Average 90 stars, based on 1 article reviews
cyclic lipopeptide antibiotics daptomycin cubicin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Cubist Pharmaceuticals cyclic lipopeptide daptomycin
Infection Parameter
Cyclic Lipopeptide Daptomycin, supplied by Cubist Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cyclic+lipopeptides+daptomycin/cyclic+lipopeptide+daptomycin/10__1128_slash_aac__00084___09-191-9-2
Average 90 stars, based on 1 article reviews
cyclic lipopeptide daptomycin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Antibacterial efficacy by SCF in the absence or presence of valine. ( A ) Percent survival of MRSA2 in the presence of the indicated antibiotics with or without 5 mM valine. SCF, cefoperazone sodium and sulbactam sodium; ASPC, amoxicillin sodium clavulanate potassium. Antibiotic doses are as follows: 200 µg/mL for SCF; 300 µg/mL for ceftriaxone, cefradine, ceftazidime, cefazolin; 150 µg/mL for vancomycin; and 400 µg/mL for the others. ( B ) Percent survival of MRSA2 in the absence or presence of the indicated concentrations of SCF plus 5 mM valine. ( C ) Percent survival of MRSA2 in the absence or presence of the indicated concentrations of valine plus 200 µg/mL SCF. ( D ) Percent survival of MRSA2 in the absence or presence of the indicated incubation time with 5 mM valine and 200 µg/mL SCF. ( E ) Percent survival of 18 MRSA isolates (2.5 × 10 7 CFU/mL) in the absence or presence of 5 mM valine, 200 µg/mL SCF, and both. ( F ) Bacterial load of liver, kidney, and spleen of mice infected with MRSA2. Mice were intraperitoneally infected with 2.5 × 10 6 CFU of MRSA2 and divided into four groups, four male Balb/c mice per group. The four groups were separately intravenously injected with saline solution, 200 mg/kg SCF, 200 mg/kg valine, or both in an hour later. Spleen, kidney, and liver of these treated mice were collected at 24 h and homogenized for spot plate counting. ( G ) Percent survival of mice in the absence or presence of the indicated dose of SCF or/and the indicated dose of valine. Mice were intraperitoneally infected with 2.5 × 10 7 CFU of MRSA2 and divided into eight (sub)groups to be treated as the indicated post 1 h of infection, 10 mice per group. Survival of mice was monitored for 7 days. ( H ) Bacterial load of mouse thigh infected with MRSA2. Mice were intramuscularly infected with 2.8 × 10 5 CFU of MRSA2 and divided into four groups. The four groups were separately treated with saline solution, 200 mg/kg SCF, 200 mg/kg valine, or both post 2 h infection. The thigh muscle infected was collected at 26 h and homogenized for spot plate counting. ( I ) Percent survival of MRSA2 in the absence or presence of 5 mM leucine or isoleucine plus 200 µg/mL SCF. Data are mean ± SD from three biological replicates. *, P < 0.05; **, P < 0.01.

Journal: mSystems

Article Title: Valine potentiates cefoperazone-sulbactam to kill methicillin-resistant Staphylococcus aureus

doi: 10.1128/msystems.01244-24

Figure Lengend Snippet: Antibacterial efficacy by SCF in the absence or presence of valine. ( A ) Percent survival of MRSA2 in the presence of the indicated antibiotics with or without 5 mM valine. SCF, cefoperazone sodium and sulbactam sodium; ASPC, amoxicillin sodium clavulanate potassium. Antibiotic doses are as follows: 200 µg/mL for SCF; 300 µg/mL for ceftriaxone, cefradine, ceftazidime, cefazolin; 150 µg/mL for vancomycin; and 400 µg/mL for the others. ( B ) Percent survival of MRSA2 in the absence or presence of the indicated concentrations of SCF plus 5 mM valine. ( C ) Percent survival of MRSA2 in the absence or presence of the indicated concentrations of valine plus 200 µg/mL SCF. ( D ) Percent survival of MRSA2 in the absence or presence of the indicated incubation time with 5 mM valine and 200 µg/mL SCF. ( E ) Percent survival of 18 MRSA isolates (2.5 × 10 7 CFU/mL) in the absence or presence of 5 mM valine, 200 µg/mL SCF, and both. ( F ) Bacterial load of liver, kidney, and spleen of mice infected with MRSA2. Mice were intraperitoneally infected with 2.5 × 10 6 CFU of MRSA2 and divided into four groups, four male Balb/c mice per group. The four groups were separately intravenously injected with saline solution, 200 mg/kg SCF, 200 mg/kg valine, or both in an hour later. Spleen, kidney, and liver of these treated mice were collected at 24 h and homogenized for spot plate counting. ( G ) Percent survival of mice in the absence or presence of the indicated dose of SCF or/and the indicated dose of valine. Mice were intraperitoneally infected with 2.5 × 10 7 CFU of MRSA2 and divided into eight (sub)groups to be treated as the indicated post 1 h of infection, 10 mice per group. Survival of mice was monitored for 7 days. ( H ) Bacterial load of mouse thigh infected with MRSA2. Mice were intramuscularly infected with 2.8 × 10 5 CFU of MRSA2 and divided into four groups. The four groups were separately treated with saline solution, 200 mg/kg SCF, 200 mg/kg valine, or both post 2 h infection. The thigh muscle infected was collected at 26 h and homogenized for spot plate counting. ( I ) Percent survival of MRSA2 in the absence or presence of 5 mM leucine or isoleucine plus 200 µg/mL SCF. Data are mean ± SD from three biological replicates. *, P < 0.05; **, P < 0.01.

Article Snippet: All antibiotics tested, including vancomycin (glycopeptides), cefoperazone sodium and sulbactam sodium (cephalosporins), daptomycin (cyclic lipopeptides), oxacillin (penicillins) were purchased from Sangon Biotech (BBI) Limited (Shanghai, China).

Techniques: Incubation, Infection, Injection, Saline

Selected antibiotics tested against B. burgdorferi

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Borrelia burgdorferi , the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells

doi: 10.1128/AAC.00864-15

Figure Lengend Snippet: Selected antibiotics tested against B. burgdorferi

Article Snippet: Daptomycin cyclic lipopeptide (Sigma) was dissolved in a 5 μg/ml solution of calcium chloride.

Techniques:

Killing of B. burgdorferi by daptomycin. Time-dependent killing of stationary-phase B. burgdorferi exposed to daptomycin (81 μg/ml) (n = 3). Error bars represent standard errors.

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Borrelia burgdorferi , the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells

doi: 10.1128/AAC.00864-15

Figure Lengend Snippet: Killing of B. burgdorferi by daptomycin. Time-dependent killing of stationary-phase B. burgdorferi exposed to daptomycin (81 μg/ml) (n = 3). Error bars represent standard errors.

Article Snippet: Daptomycin cyclic lipopeptide (Sigma) was dissolved in a 5 μg/ml solution of calcium chloride.

Techniques:

Infection Parameter

Journal: Journal of Cardiothoracic Surgery

Article Title: Treatment of gram-positive deep sternal wound infections in cardiac surgery -experiences with daptomycin-

doi: 10.1186/1749-8090-6-112

Figure Lengend Snippet: Infection Parameter

Article Snippet: The first in a novel class of cyclic lipopeptide antibiotics daptomycin (Cubicin; Cubist Pharmaceuticals, Inc., Lexington, MA), has already been proven to be effective in the treatment of bacteremia and endocarditis caused by MRSA and several case reports document about its effectiveness in the field of cardiac surgery [ - ].

Techniques: Infection

Laboratorial data

Journal: Journal of Cardiothoracic Surgery

Article Title: Treatment of gram-positive deep sternal wound infections in cardiac surgery -experiences with daptomycin-

doi: 10.1186/1749-8090-6-112

Figure Lengend Snippet: Laboratorial data

Article Snippet: The first in a novel class of cyclic lipopeptide antibiotics daptomycin (Cubicin; Cubist Pharmaceuticals, Inc., Lexington, MA), has already been proven to be effective in the treatment of bacteremia and endocarditis caused by MRSA and several case reports document about its effectiveness in the field of cardiac surgery [ - ].

Techniques: